Immunovant, Inc. IMVT Cash Flow Statement
| Q4 '26 | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | ||
|---|---|---|---|---|---|---|
| -$147.86M-38.9% | -$110.64M+0.4% | -$126.5M-15.9% | -$120.61M-38.4% | -$106.45M-41.3% | ||
| $96K-11.9% | $101K+2.0% | $105K+18.0% | $107K+33.8% | $109K+70.3% | ||
| $11.14M-4.7% | $12.72M+9.1% | $13.36M+5.2% | $18.51M+37.6% | $11.69M+20.7% | ||
| -$563K-562% | -$319K— | $0+100% | -$129K+95.6% | -$85K-102% | ||
| -$1.35M— | —— | -$1.07M-111% | -$9.4M-342% | —— | ||
| -$1.3M-767% | $38K— | -$167K-102% | $1.36M— | $195K— | ||
| -$4.31M-128% | -$2.87M-155% | -$1.16M-125% | -$498K-127% | $15.21M— | ||
| $26K+18.2% | $25K+8.7% | $24K+9.1% | $24K-63.6% | $22K-91.3% | ||
| -$95.06M+14.1% | -$92.33M+8.0% | -$102.52M-15.6% | -$117.41M-54.1% | -$110.64M-85.3% | ||
| $8K-96.0% | $0-100% | $0-100% | $0-100% | $201K+34.0% | ||
| -$8K+96.0% | $0+100% | $0+100% | $0+100% | -$201K-34.0% | ||
| $0-100% | $516.68M+36,589% | $24.6M+3,269% | $2.92M+325% | $450M-4.0% | ||
| $3.64M-99.2% | $564.6M+22,814% | $24.6M+3,269% | $2.92M+325% | $450.61M+29,066% | ||
| -$988K— | $377K— | $878K-16.3% | -$566K-269% | —— | ||
| —— | $472.66M+581% | -$77.04M+11.5% | -$115.06M-52.7% | $339.29M— | ||
| —— | $1.64M— | —— | —— | $901K+77.0% | ||
| $96K-11.9% | $101K+2.0% | $105K+18.0% | $107K+33.8% | $109K+70.3% | ||
| -$1.35M— | —— | -$1.07M-111% | -$9.4M-342% | —— | ||
| —— | $756K-81.7% | $10.26M-3.6% | -$5.3M+30.3% | —— | ||
| -$4.31M-128% | -$2.87M-155% | -$1.16M-125% | -$498K-127% | $15.21M— | ||
| $26K+18.2% | $25K+8.7% | $24K+9.1% | $24K-63.6% | $22K-91.3% | ||
| $126K-60.5% | $126K— | $126K— | $126K— | $319K-78.8% | ||
| $18.25K-81.4% | $18.25K— | $18.25K— | $18.25K— | $98K+331% | ||
| -$95.07M+14.2% | -$92.33M+8.2% | -$102.52M-15.4% | -$117.41M-53.7% | -$110.84M-85.2% | ||
| -$95.07M+14.2% | -$92.33M+8.2% | -$102.52M-15.4% | -$117.41M-53.7% | -$110.84M-85.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Immunovant, Inc. generate?
- Immunovant, Inc. (IMVT) generated -$407.3M in operating cash flow over the trailing twelve months.
- What is Immunovant, Inc.'s free cash flow?
- After $8.0K of capital expenditures, Immunovant, Inc.'s free cash flow was -$407.3M over the trailing twelve months, down 8.2% year over year.
- Where does Immunovant, Inc.'s cash flow data come from?
- Every line is extracted from Immunovant, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.